{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,730M vs. cons $1,699M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "TAVR Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,255M vs. cons $1,233M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "TMTT Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$192M vs. cons $186M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Total Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$6.80B midpoint vs. cons $6.75B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$3.05 midpoint vs. cons $3.01",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "NCD/TAVR qualitative commentary (FY 2026)",
      "prediction": "BETTER",
      "answer": "Confident framing on asymptomatic AS; Sept 13 NCD final decision; PROGRESS update",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 4.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 estimate revisions track implied H2 raise; no implicit cut risk; short base too low to amplify",
  "day5_confidence": "MEDIUM"
}